目的:总结56例霍奇金淋巴瘤(HL)的临床特点、疗效,分析影响缓解及生存的危险因素。方法:回顾性分析56例HL患者资料,选择ABVD作为一线方案,进展及复发患者给予二线治疗,根据分期及有无不良预后因素等决定治疗疗程,放疗指征参照NCCN指南。治疗结束后做疗效及不良反应评价。采用SPSS17.0统计软件分析影响缓解率及生存的危险因素。结果:HL占同期新发淋巴瘤患者总数的7.6%,≤40岁患者占总患者数的53.6%,未见发病年龄双峰特征。56例患者病理类型100%为cHL,结节硬化型和混合细胞型共占到89.2%,二者的比例为1∶1;首次就诊71.4%患者处于Ⅲ期及Ⅳ期,60.7%患者有B组症状。巨块型病例占12.5%。纵膈、颈部、腋下淋巴结最易受累。24例(42.9%)存在结外累及,其中11例有骨累及,10例累及肺部。47例患者可进行疗效评价,其中完全缓解68.1%,部分缓解6.4%,病情稳定14.9%,病情进展10.6%。观察到ABVD方案期间出现Ⅲ度血液学毒性、肺部并发症各有4例患者。在平均随访的34个月,共有5例达到CR患者复发,6例死亡。2年及3年无病生存、总体生存分别为76.5%、60.0%;85.3%、75.0%。结论:早期识别预后不良年轻患者并给予强化治疗,加强并发症监测,HL的生存情况将得到进一步提高。 Objective: To summarize the clinical features and curative effects of 56 cases of Hodgkin ’s lymphoma (HL) and to analyze the risk factors that affect the relief and survival. Methods: The data of 56 patients with HL were retrospectively analyzed. ABVD was selected as the first-line regimen. Second-line treatment was given to patients with advanced or recurrent disease. The treatment course was decided according to the stage and whether there were adverse prognostic factors. The indications of radiotherapy were referred to the NCCN guidelines. Efficacy and side effects after treatment evaluation. SPSS17.0 statistical software was used to analyze the risk factors influencing the remission rate and survival. Results: HL accounted for 7.6% of the total number of newly diagnosed lymphoma patients in the same period and 53.6% of patients ≤40 years of age. There was no bimodal characteristics of age at onset. The pathological types of 56 patients were 100% cHL, nodular sclerosis and mixed cell type accounted for 89.2%, the ratio of the two was 1: 1; first visit 71.4% of patients in stage Ⅲ and Ⅳ, 60.7% of patients with B Group symptoms. Huge block cases accounted for 12.5%. Mediastinum, neck, underarm lymph nodes most affected. Twenty-four patients (42.9%) had extranodal involvement, of which 11 had bone involvement and 10 had pulmonary involvement. Forty-seven patients were evaluated for efficacy, with complete response 68.1%, partial response 6.4%, stable condition 14.9%, and disease progression 10.6%. Grade III hematologic toxicity was observed during the ABVD regimen and 4 patients each had pulmonary complications. During the mean follow-up of 34 months, a total of 5 patients achieved CR recurrence and 6 died. 2 years and 3 years disease-free survival, the overall survival were 76.5%, 60.0%; 85.3%, 75.0%. Conclusion: Early identification of poor prognosis in young patients with intensive treatment and to strengthen the monitoring of complications, HL survival will be further improved.